AP
EGRX

Advisors Preferred’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Advisors Preferred’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-925
Closed -$73K – 298
2017
Q2 		$73K Buy
+925
New +$75.6K 0.04% 117

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Advisors Preferred's EGRX Position: Q3 2017 in Review

Advisors Preferred sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2017, closing a stake of 925 shares — an estimated $73K sold.

Advisors Preferred first reported a position in EGRX in Q2 2017 and held it in 1 quarter. The position peaked at $73K in Q2 2017. 169 funds tracked by Wall St. Rank hold EGRX as of Q3 2017.

  • Advisors Preferred reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Advisors Preferred sold 925 Eagle Pharmaceuticals, Inc. shares in Q3 2017, an estimated $73K.
  • Advisors Preferred first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Advisors Preferred's Eagle Pharmaceuticals, Inc. position peaked at $73K in Q2 2017.
  • 169 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2017.

Based on Advisors Preferred's 13F filing for Q3 2017, filed 31 Oct 2017.